Wellington Management Group LLP Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Wellington Management Group LLP purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 223,811 shares of the medical equipment provider's stock, valued at approximately $20,022,000. Wellington Management Group LLP owned 0.33% of Lantheus as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC increased its stake in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Lantheus during the 4th quarter valued at about $36,183,000. Finally, Keybank National Association OH bought a new position in Lantheus during the 4th quarter valued at approximately $27,526,000. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Finally, B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $132.67.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,068 shares of company stock valued at $3,008,051. 1.50% of the stock is owned by insiders.

Lantheus Stock Up 2.5%

Shares of NASDAQ LNTH traded up $1.94 during trading on Wednesday, reaching $79.63. 1,050,214 shares of the company traded hands, compared to its average volume of 996,243. The firm has a 50 day simple moving average of $90.93 and a 200-day simple moving average of $91.63. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The stock has a market capitalization of $5.51 billion, a PE ratio of 13.25 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus's quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.69 earnings per share. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.